Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning.

by Attila Tordai, Andras Bors, Katalin Piroska Kiss, Katalin Balassa, Hajnalka Andrikovics, Arpad Batai, Aniko Szilvasi, Katalin Rajczy, Dora Inotai, Eva Torbagyi, Lilla Lengyel, Aniko Barta, Peter Remenyi, Tamas Masszi
Published 2019-01-01